The female infertility market is expected to grow moderately from $1.6bn in 2023 to $2.3bn in 2033, at a compound annual growth rate (CAGR) of 3.5% across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), according to GlobalData’s Female Infertility: Seven Market Drug Forecast and Market Analysis report.

Aytu BioScience, Inc. (NASDAQ: AYTU) announced on 10/11/18 the issuance of a U.S. patent covering the company's proprietary MiOXSYS® diagnostic platform for male infertility. This is the first patent specifically covering fertility measurement methods with the MiOXSYS System and is the 15th U.S. patent overall covering the system's core oxidation-reduction potential (ORP) technology and its uses. The newly issued patent expires November 24, 2035.